Results 151 to 156 of about 4,697 (156)

Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis

Clinical Therapeutics, 2020
Pauline Le Nouveau, Matthew S Davids, Gautamjeet Mangat   +2 more
exaly  

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Lancet, The, 2018
Andre H Goy, Simon A Rule, Michael Wang
exaly  

Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats

Journal of Pharmaceutical and Biomedical Analysis, 2019
David Paul, N Satheeshkumar
exaly  

A Manufacturing Process to an Intermediate in the Synthesis of Acalabrutinib

Organic Process Research and Development, 2018
Michael Golden
exaly  

Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization Open Access

ImmunoHorizons
Hans W. Prozesky, Veerendra munugalavadla, Alfredo Guerreros   +2 more
exaly  

Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib

Future Oncology
Bruno Emond, Marie-Helene Lafeuille, Moshe Yair Levy   +2 more
exaly